

Report from the NCI Acting Director

*Douglas R. Lowy
Acting Director, National Cancer Institute
National Institutes of Health*


FNLAC Meeting
May 8, 2017



NATIONAL CANCER INSTITUTE



NCI APPROPRIATIONS 2013-2017 (in billions)




Doug Lowy & Tony Fauci with Senator Roy Blunt & Congressman Tom Cole (May 2, 2017)





Research Program Grants (RPGs)

New RPG Awards (types 1 & 2): FY13 to FY16





Percent R01 and R21 Awards to ESI's & NI's (FY13-FY16)

| | FY13 | FY14 | FY15 | FY16 |
|---------------------------------------|------------|------------|------------|------------|
| R01: All New Investigators | 25% | 25% | 20% | 24% |
| R01: Early Stage Investigators | 16% | 15% | 11% | 13% |
| R21: All New Investigators | 45% | 40% | 40% | 40% |



NCI/NIH BUDGET PROCESS FOR REGULAR APPROPRIATION

STEP 1



White House OMB coordinates with federal agencies to formulate the President's budget proposal

FY 2018

STEP 2



Congressional appropriations committees consider President's proposal & prepare legislation

STEP 3



Congress reconciles & finalizes appropriations legislation & sends to the President

STEP 4




President signs the appropriations bill into law making funds available for NIH & NCI

FY 2017



CANCER MOONSHOT: AUTHORIZED FUNDING






CANCER MOONSHOT: AUTHORIZED FUNDING

| Fiscal Year | Cures Dollars (in millions) | Estimated First Year Awards (in millions) |
|--------------------|--|--|
| 2017 | \$300 | \$140 |
| 2018 | \$300 | \$105 |
| 2019 | \$400 | \$60 |
| 2020 | \$195 | \$0 |
| 2021 | \$195 | \$0 |
| 2022 | \$194 | \$30 |
| 2023 | \$216 | \$25 |




CANCER MOONSHOT: IMPLEMENTATION



ICPC (International Cancer Proteogenome Consortium)

10 MOUs / **11** countries /
18 institutions



Australia

Team: Macquarie University, Children's Medical Research Institute, Garvan Institute of Medical Research, and Bioplatforms Australia Ltd.

Canada/Germany

Team: McGill University, University of Victoria, University of British Columbia, and Leibniz Institute for Analytical Sciences

China

Team: Shanghai Institute of Materia Medica, Chinese Academy of Science, and Fudan University

Japan

Team: National Cancer Center Japan

South Korea

Team: Korea Institute of Science and Technology

Sweden

Team: Lund University

Switzerland

Team: ETH Zürich

Taiwan

Team: Academia Sinica
Team: Chang Gung University

United Kingdom

Team: University of Manchester, and University of Dundee

United States

Team: NCI Clinical Proteomic Tumor Analysis Consortium



International Cancer Proteogenome Consortium (San Diego CA March 19, 2017)





NATIONAL CANCER INSTITUTE